Oliver North
Junior Member
anyways, stats can be found here:
http://www.ncpa.org/pub/ba596
http://www.ncbi.nlm.nih.gov/pubmed/18639491
and a critique of the claim, which notes a couple of the same caveats I did (ability to pay for instance). Interesting things to note:
It’s certainly the case that we have higher survival rates than the United Kingdom and other countries with nationalized health care. Across the board, the United States boasts a higher five-year relative survival rate than the European average, according to a 2008 study in the British medical journal Lancet. For breast cancer, for instance, the U.S. survival rate was 83.9 percent, the U.K. rate was 69.7, and the average European rate was 73.1.But survival rates also differ within the United States, between insured and uninsured populations.
[...]
survival rates in Canada, Japan, Australia and Cuba were all comparable to or higher than U.S. survival rates on all types of cancer that the Lancet study examined, except for prostate cancer. Those countries all have some form of government-provided health care coverage. Prostate cancer often doesn’t require treatment, so the aggressive screening common in the U.S. turns up both early cases and cases that would never need intervention.
[...]
early detection will always increase survival rates, even if it doesn’t improve outcomes (though oncologists do agree that cancer is less deadly if found early). If two people have exactly the same disease progression, the one who’s diagnosed earlier will be more likely to be alive in five years. Thus, countries with more advance screening will have higher survival rates even if they don’t have better post-diagnosis care. Cancer screening is less widespread in European countries, and people without insurance or who are on Medicaid also are less likely to have access to it. The ACS study showed that the uninsured and Medicaid beneficiaries had lower rates of both mammograms and colorectal cancer screening than the insured.
[...]
So the survival statistics, while they might be useful for some kinds of comparisons, don’t really present any obvious conclusions when used to compare different populations. They can be interpreted to argue for leaving the U.S. system alone, or for extending coverage to the millions who don’t have it.
http://www.factcheck.org/2009/08/cancer-rates-and-unjustified-conclusions/
so, the claim that rates are better is true, and I went to pains to point out that I didn't think this meant the American system was better, only that it has strengths (early detection, for instance).